The term biofilm describes the structurally complex bacterial BRIEF COMMUNICATION
|
|
- Darlene Wade
- 6 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8: BRIEF COMMUNICATION Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant Helicobacter pylori: A Clinical Trial GIOVANNI CAMMAROTA,* GIOVANNA BRANCA, FAUSTA ARDITO, MAURIZIO SANGUINETTI, GIANLUCA IANIRO,* ROSSELLA CIANCI,* RICCARDO TORELLI,* GIOVANNA MASALA, ANTONIO GASBARRINI,* GIOVANNI FADDA, RAFFAELE LANDOLFI,* and GIOVANNI GASBARRINI* *Institute of Internal Medicine and Institute of Microbiology, Catholic University of Medicine and Surgery, Rome, Italy; and Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute, Florence, Italy BACKGROUND & AIMS: Helicobacter pylori attaches to gastric mucosa and grows as a biofilm. This constitutes protection from antimicrobial agents. We assessed the role of a pretreatment with n-acetylcysteine in destroying biofilm and overcoming H pylori antibiotic resistance. METHODS: In an open-label, randomized controlled trial, 40 subjects with a history of at least 4 H pylori eradication failures were evaluated for biofilm presence, antibiotic susceptibility, and H pylori genotypes. Subjects were assigned randomly to receive (group A) or not (group B) n-acetylcysteine before a culture-guided antibiotic regimen. The primary end point was the H pylori eradication rate as assessed by 13 C- labeled urea breath testing. RESULTS: H pylori was eradicated in 13 of 20 (both per-protocol and intention-to-treat analyses, 65%; 95% confidence interval, 44% 86%) group A participants and 4 of 20 (both per-protocol and intention-to-treat analyses, 20%; 95% confidence interval, 3% 37%) group B participants (P.01). Biofilms persisted only in unsuccessfully treated participants. H pylori genotypes did not influence treatment outcome. CONCLUSIONS: N-acetylcysteine pretreatment before a culture-guided antibiotic regimen is effective in overcoming H pylori antibiotic resistance. Keywords: Biofilm; Helicobacter pylori; Rescue Therapy; Resistance. The term biofilm describes the structurally complex bacterial ecosystems that allow bacteria to survive in unfavorable environments by enclosing themselves in an exopolysaccharide matrix. 1 Biofilm-producing bacteria are more resistant to antibiotics presumably owing to slow or incomplete penetration of the antibiotic into the biofilm. 2 Biofilm formation also guarantees decreased metabolic and growth rates, leading to a lower susceptibility to antimicrobials. 2 A reliable mechanism to eradicate these resistant infections therefore consists of eliminating biofilm. 1 Several studies have shown the ability of Helicobacter pylori to form biofilm. 3,4 The possible survival of biofilm outside the gastric niche has been suggested as a probable transmission mode for this organism. 5 Two distinct studies have shown the presence of biofilm on the gastric mucosa of H pylori positive subjects, as well as the absence of biofilm in H pylori negative control subjects. 6,7 Study Aim We tested the hypothesis that a mucolytic pretreatment was able to demolish the biofilm architecture, rendering H pylori resistant strains more vulnerable to antibiotics. Materials and Methods Study Design In the first part of the study, we determined in vitro the ability of N-acetylcysteine (NAC) to interfere with H pylori biofilm formation or to provoke its demolition. In a second phase, we conducted a prospective, open-label, randomized trial to assess the effect of NAC pretreatment on the efficacy of a culture-guided antibiotic regimen in patients with a history of multiple treatment failures against H pylori. Patients gastric mucosa also was investigated for biofilm presence before and after treatment. Finally, genetic studies on antibiotic resistance and vacuolating cytotoxin A/cytotoxin-associated gene-a determinants were performed on cultured H pylori isolates. The primary end point of the study was to evaluate the H pylori eradication rate as assessed by urea breath testing at least 2 months from the end of antibiotic treatment. The study was approved by the ethics committee of our University (Clinical- Trials.gov, number NCT ). Patients provided written informed consent to participate in the study. In Vitro Study Gastric biopsy specimens from 10 patients with a history of at least 4 failed H pylori eradication attempts were cultured for H pylori in accordance with methods described elsewhere. 8 Specimens from 5 patients were cultured with added NAC 2 mg/ml. Both NAC-containing and NAC-lacking trays were tested for biofilm formation as described. 3 NAClacking trays then were tested, in 3 different plates, upon addition of increasing concentration of NAC broth (2, 10, and 20 mg/ml) to assess biofilm quantity. Biofilm formation was quantified as previously described. 3 By subtracting the percentage transmittance (%T) value for each Abbreviations used in this paper: NAC, N-acetylcysteine; %T bloc, percentage transmittance blocked by the AGA Institute /$36.00 doi: /j.cgh
2 818 CAMMAROTA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 9 test sample from the %T value of the blank reagent, we calculated the amount of blocked light through the wells (%T bloc ). Biofilm production by each isolate was scored as follows: negative (%T bloc 0 10); biofilm producers (1, %T bloc 10 20; 2, %T bloc 20 35; 3,%T bloc 35 50; or 4,%T bloc 50). Positive and negative controls were a known H pylori biofilm and a brucella broth, respectively. Figure 1. (A) Scanning electron micrograph of gastric mucosal surface covered in a blanket of biofilm before the treatment. (B) Biofilm disappearance after H pylori eradication. Clinical Study Patient recruitment. Consecutive patients who had a history of at least 4 H pylori eradication failures, and were therefore referred to our tertiary endoscopy center for endoscopic examination and H pylori culture, were recruited. Patients affected by serious concomitant illnesses and those with recent or continuing use of antibiotics were excluded. Fourteen patients who had interrupted at least one of the previous eradication treatments because of adverse events were not included. Two eligible patients also were excluded when their H pylori strains did not survive culture processing. H pylori characterization. Two gastric biopsy specimens were used for biofilm demonstration by scanning electron microscopy. As in other reports, 6,7 a biofilm architecture was defined as a dense accumulation of bacteria within an amorphous matrix (Figure 1A). Two additional specimens were used for H pylori culture: antibiotic susceptibility testing, and genetic analysis. For each strain, minimal inhibitory concentrations were obtained for amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin by the epsilometer test method (AB Biodisk, Solna, Sweden). 9,10 The 23S, gyra, and gyrb gene mutations (for clarithromycin and quinolone resistance, respectively), as well as vacuolating cytotoxin A and cytotoxinassociated gene-a genotypes of H pylori isolates, were analyzed as previously described Patient randomization and follow-up evaluation. Patients were assigned randomly, using a computer-assisted allocation method, to 1 of 2 different eradication schedules: group A received a 1-week treatment course with NAC 600 mg once a day before a culture-guided 1-week antibiotic regimen, including a proton pump inhibitor plus 2 antibiotics; and group B (control) received solely a 1-week culture-guided antibiotic treatment, including a proton pump inhibitor plus 2 antibiotics. Sensitive antibiotics were chosen on the basis of minimal inhibitory concentration values. Side effects were recorded 1 week after treatment by a questionnaire. Treatment compliance was measured by pill count, together with a patient interview. At least 2 months after the end of therapy, patients underwent urea breath testing to determine their H pylori status. At that time, patients had to discontinue any acid-suppressive therapy for at least 2 weeks. Patients also were invited to repeat endoscopic examination for biofilm monitoring. Statistical Analysis We calculated the sample size by considering the proportion of patients successfully treated as the primary outcome measure. Based on our experience, we predicted an eradication rate in the standard group (group B) in the range of 15% to 20%. Therefore, setting an alpha value of.05, with 20 patients allocated to the treatment arm (group A) and 20 patients allocated to the control arm (group B, standard treatment), we had a power of 80% to observe the following: an eradication rate of 40% in the treatment arm with an expected eradication rate of 15% for the control group (eradication rate difference, 25%), or an eradication rate of 47% in the treatment arm with an expected eradication rate of 20% for the control group (eradication rate difference, 27%). The success rate was calculated as the percentage of patients whose H pylori infection was cured. Both per-protocol and intention-to-treat analyses were performed. The 95% confidence interval for a binomial variable was calculated. The Fisher exact test was performed using SAS statistical software (SAS/STAT version 9.1; SAS Institute Inc, Cary, NC). Treatment results also were compared in light of the genetic findings. Results In Vitro Study None of the 5 H pylori isolates cultured with NAC 2 mg/ml developed biofilm (%T bloc negative). Biofilm did develop in the other 5 plates, in which cultures had not been enriched with NAC. In these NAC-lacking cultures, NAC supplementation determined a progressive biofilm reduction until its disappearance (Table 1). Clinical Study A total of 40 patients were recruited for the study treatment: 20 in group A (8 men; mean age, 49 y) and 20 in group B (10 men; mean age, 47 y). All patients completed the treatment. Thirteen group A subjects were eradicated (both
3 September 2010 H PYLORI BIOFILM AND RESCUE TREATMENT 819 Table 1. Results of the In Vitro Study Patient number Developed biofilm NAC, 2 mg/ml NAC, 10 mg/ml NAC, 20 mg/ml Positive control (H pylori biofilm) Brucella broth (negative control) Negative Negative 4 Negative Negative Negative 4 Negative Negative Negative 4 Negative Negative Negative 4 Negative Negative Negative 4 Negative NOTE. H pylori isolates from 5 patients were cultured without NAC and all developed biofilm. Thereafter, each isolate was challenged, in 3 different plates, with increasing concentrations of NAC. The amount of blocked light through the wells (%T bloc ) was calculated and compared with control cultures. per-protocol and intention-to-treat analyses, 65%; 95% confidence interval, 44% 86%), whereas only 4 group B patients were treated successfully (both per-protocol and intention-to-treat analyses, 20%; 95% confidence interval, 3% 37%) (P.01). Overall, 14 (35%) subjects (6 in group A and 8 in group B) reported mild adverse effects (diarrhea, abdominal pain, stomatitis). At recruitment, scanning electron microscopy analysis documented biofilm in all recruited patients (100%). A total of 24 patients (60%) (14 in group A and 10 in group B) agreed to repeat endoscopic examination after treatment. Ten of these patients were eradicated, whereas 14 were still H pylori positive. Scanning electron microscopy analysis showed the disappearance of biofilm in all patients (100%) in whom the microorganism was eradicated (Figure 1B). H pylori cytotoxin-associated gene-a and vacuolating cytotoxin A status did not affect eradication outcome or biofilm status. Antibiotic susceptibility testing data and genetic findings are detailed in the Supplementary information (see Supplementary Tables 1 and 2). Discussion A standard rescue therapy against H pylori is still lacking, and antimicrobial sensitivity testing currently is recommended for patients who have failed eradication therapy. 14 In Figure 2. Representation of the findings of this study. (A) NAC was effective both in inhibiting the biofilm formation and in destroying developed biofilms in cultured H pylori isolates. (B) A NAC pretreatment course before a culture-guided antibiotic regimen is more effective in eradicating resistant H pylori infection than antibiotics alone.
4 820 CAMMAROTA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 9 this study, we performed a novel approach to achieve H pylori eradication after multiple treatment failures, based on the hypothesis that microbial biofilm may support the tenacious resistance of H pylori to antibiotics. NAC might act as a biofilmdissolving agent, thus sensitizing H pylori to antibiotic action. These mechanisms already have been hypothesized for bacteria responsible for pulmonary infection. 15,16 In this study, we first proved, in vitro, that NAC was effective both in inhibiting the H pylori biofilm formation and in destroying developed biofilms. Moreover, keeping with data from the published literature, 6,7,17 we documented H pylori biofilm presence at scanning electron microscopy analysis in all patients enrolled for the clinical study. After treatment, we showed the disappearance of biofilm in all patients who repeated endoscopy and were treated successfully. Finally, H pylori was eradicated in 65% of patients treated with NAC before a culture-guided antibiotic regimen, compared with an eradication rate in control group B of only 20% (P.01) (Figure 2). Larger studies will be necessary to confirm our results and clarify whether treatment success can be improved by increasing the dosage of or the exposure to NAC before or during antibiotic treatment. New strategies are being envisaged to design substances that can either inhibit biofilm formation or destabilize biofilms. 18 Supplementary Tables 1, 2 and Figure 1. Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at and at doi: / j.cgh References 1. Costerton, JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284: Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358: Cole SP, Harwood J, Lee R, et al. Characterization of monospecies biofilm formation by Helicobacter pylori. J Bacteriol 2004; 186: Stark RM, Gerwig GJ, Pitman RS, et al. Biofilm formation by Helicobacter pylori. Lett Appl Microbiol 1999;28: Percival SL, Thomas JG. Transmission of Helicobacter pylori and the role of water and biofilms. J Water Health 2009;7: Carron MA, Tran VR, Sugawa C, et al. Identification of Helicobacter pylori biofilms in human gastric mucosa. J Gastrointest Surg 2006;10: Coticchia JM, Sugawa C, Tran VR, et al. Presence and density of Helicobacter pylori biofilms in human gastric mucosa in patients with peptic ulcer disease. J Gastrointest Surg 2006;10: Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a cultureguided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004;19: Osato MS, Reddy R, Reddy SG, et al. Comparison of the E-test and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 2001;17: Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: Posteraro P, Branca G, Sanguinetti M, et al. Rapid detection of clarithromycin resistance in Helicobacter pylori using a PCRbased denaturing HPLC assay. J Antimicrob Chemother 2006; 57: Hung KH, Sheu BS, Chang WL, et al. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009;14: Cellini L, Grande R, Di Campli E, et al. Characterization of an Helicobacter pylori environmental strain. J Appl Microbiol 2008; 105: Malfertheiner P, Megraud F, O Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56: Legnani D. Acute bacterial exacerbation of chronic obstructive pulmonary disease and biofilm. Infez Med 2009;17(Suppl 2): Macchi A, Ardito F, Marchese A, et al. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/ aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J Chemother 2006;18: Cellini L, Grande R, Di Campli E, et al. Dynamic colonization of Helicobacter pylori in human gastric mucosa. Scand J Gastroenterol 2008;43: Del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther 2007;82: Reprint requests Address requests for reprints to: Giovanni Cammarota, MD, A. Gemelli University Hospital, Department of Internal Medicine, Largo A. Gemelli, 8, Roma, Italy. gcammarota@rm.unicatt.it; fax: (39) Conflicts of interest The authors disclose no conflicts. Funding The study was funded by the Italian Ministry for University, Scientific, and Technological Research.
5 820.e1 CAMMAROTA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 9 Supplementary Table 1. Drug Assumption History of the 20 Patients Treated With NAC Before a Culture-Guided, Antibiotic-Based Regimen (Group A) Patient number PPI- and NAC-associated, culture-guided antibiotics Successful eradication Number of previous failed eradication attempts Previous antibiotic assumption (number of times) 23S/GyrA/GyrB mutation VacA/CagA profile E-test results sensitive/ resistant 1 A-L Yes 6 A (5), L (4), C (3), M (2), T (2) 2 A-L No 4 A (4), M (2), C (2), 3 A-C Yes 4 A (4), M (2), L (2), C (1), T (1) 4 A-L No 7 A (7), C (4), L (4), M (3), T (3) 5 A-T No 4 A (3), C (2), M (1), L (1), T (1) 6 A-T Yes 4 A (4), C (1), M (1), L (1), T (1) 7 A-L No 7 A (6), C (5), M (3), L (3), T (3) 8 A-T Yes 4 A (4), C (2), M 9 A-L Yes 4 A (4), C (2), M 10 A-C Yes 4 A (4), C (1), M (3), L (1), T (1) 11 A-L Yes 5 M (4), A (3), C 12 A-C Yes 5 M (4), A (3), T (2), C (1), L (1) 13 A-T Yes 4 A (4), M (3), C 14 A-T No 6 A (6), C (3), T (3), L (3), M (1) 15 A-T Yes 5 M (4), A (3), T (2), C (1), L (1) 16 A-C No 5 A (4), M (2), L (2), C (2), T (2) 17 A-T Yes 5 A (4), M (3), C (2), T (2), L (1) 18 A-L No 6 A (6), M (3), C (2), 19 A-C Yes 5 A (5), M (2), L (2), C (2), T (2) 20 A-T Yes 4 A (4), C (2), M A2143G/WT/WT s1m2/absent A, T, L, M/C A2143G/WT/WT s2m2/p1p2p3 A, T, L/C, M WT/N87I/WT s2m2/absent A, T, C, M/L A2143G/WT/WT s1m2/absent A, T, L, M/C A2143G, T2182C/ N87K, A97V, E105G/WT s1m1/p1p2p3 A, T/L, C, M A2143G/N133K/WT s1m2/p1p2p3 A, T, L, M/C WT/WT/WT s2m2/absent A, T, L, C, M/none A2142G/D91G/WT s2m2/absent A, T/L, C, M WT/WT/WT s2m1/p1p2p2p3 A, T, C, L/M WT/WT/WT s2m2/absent A, T, L, C, M/none WT/WT/WT s2m2/absent A, T, C, L/M A2143G/N87I/WT S1m1/P1P2P2P3 A, T, M/C, L A2143G, T2182C/ N87K, A97V, E105G/WT s1m1/p1p2p2p3 A, T/C, L, M WT/WT/WT s2m1/p1p2p3 A, T, L, C, M/none WT/N87K/WT s1m2//p1p2p2p3 A, T, C/L, M A2143G/N87I/WT s2m2/absent A, T/C, L, M WT/N87I/WT s1m2/absent A, T, C/L, M A2142C/D91G/WT s2m1/p1p2p3 A, T/C, L, M A, amoxicillin; C, clarithromycin; CagA, cytotoxin-associated gene-a; L, levofloxacin; M, metronidazole; PPI, proton pump inhibitor; T, tetracycline; VacA, vacuolating cytotoxin A.
6 September 2010 H PYLORI BIOFILM AND RESCUE TREATMENT 820.e2 Supplementary Table 2. Drug Assumption History of the 20 Patients Treated With a Culture-Guided, Antibiotic-Based Regimen Alone (Group B) Patient number PPI-associated culture-guided antibiotics (without NAC) Successful eradication Number of previous failed eradication attempts Previous antibiotic assumption (number of times) 23S/GyrA/GyrB mutation VacA/CagA profile E-test results sensitive/resistant 1 A-T Yes 4 A (4),, C (1), M (1) 2 A-L No 5 A (5), L (3), C (2), 3 A-C Yes 4 A (4), L (2), C (2), 4 A-T No 6 A (6), C (3), L (3), M (3), T (3) 5 A-L No 5 A (5), L (3), C (2), M (1), T (2) 6 A-M No 5 A (5), C (2), M (2), 7 A-L No 4 A (4), C (2), L (2), T (1), M (1) 8 A-T Yes 4 A (4), M (2), C (1), L (1), T (1) 9 A-L Yes 5 A (5), C (2), M (2), 10 A-C No 4 A (4), M (2), L (2), C (1), T (1) 11 A-L No 6 A (5), T (4), L (3), M (2), C (2) 12 A-T No 5 A (5), T (3), L (3), C (2), M (1) 13 A-T No 4 A (4), C (1), L (2), 14 A-L No 6 A (6), C (2), T (3), L (3), M (2) 15 A-T No 5 A (5), L (3), T (2), C (2), M (1) 16 A-T No 4 A (4), L (2), C (1), 17 A-T No 4 A (4), M (2), T (2), L (1), C (1) 18 A-C No 5 A (5), L (2), C (2), T (2), M (2) 19 A-L No 6 A (6), M (3), C (2), 20 A-C No 5 A (5), M (3), C (2), A2142G/D91G/WT s1m1/p1p2p3 A, T/L, C, M WT/H57Y/WT s1m2/absent A, T, C, M/L A2143G/D91Y/WT s2m2/absent A, T/L, C, M A2143G/WT/WT s2m2/absent A, T, L, M/C A2142C/D91G/WT s1m1/p1p2p3 A, T, M/L, C A2143G/D91Y/WT s1m2/p1p2p3 A, T, M/L, C WT/WT/WT s1m1/p1p2p3 A, T, C, L, M/none A2142C/WT/WT s2m2/absent A, T, L/C, M A2143G/N87I/WT s1m1/p1p2p3 A, T/C, L, M WT/D91G/WT s1m1/p1p2p2p3 A, T, C/L, M WT/WT/WT s2m2/absent A, T, L, C/ M A2142G/N87I/WT s2m2/absent A, T, M/L, C A2142C/D91G/WT s1m2/p1p2p2p3 A, T, M/L, C A2143G/D91Y/WT s1m1/p1p2p2p3 A, T/C, L, M WT/H57Y/WT S2m2/absent A, T, C/L, M WT/WT/WT s2m1/p1p2p2p3 A, T, C, L/M WT/WT/WT s1m1/absent A, T, C, L/M A, amoxicillin; C, clarithromycin; CagA, cytotoxin-associated gene-a; L, levofloxacin; M, metronidazole; PPI, proton pump inhibitor; T, tetracycline; VacA, vacuolating cytotoxin A.
7 820.e3 CAMMAROTA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 9 Supplementary Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flowchart.
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationFailure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates
cp60392 Module 1 Journal of Clinical Pathology 28/8/08 12:38:20 Topics: ; Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationEfficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection
ORIGInAL PAPERs Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection Antonio Tursi 1, Marcello Picchio 2, Walter Elisei
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationHelicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens
Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationLow Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial
Global Journal of Health Science; Vol. 7, No. 1; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Low Dose Furazolidone for Eradication of H- pylori Instead of
More informationThe annual incidence of peptic ulcer disease in developed
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2003;1:273 278 Pretreatment Antimicrobial Susceptibility Testing Is Cost Saving in the Eradication of Helicobacter pylori MARCO ROMANO,* RICCARDO MARMO, ANTONIO
More informationFraming Helicobacter pylori: The Etiology of Peptic Ulcers and Gastritis
Framing Helicobacter pylori: The Etiology of Peptic Ulcers and Gastritis By Aja Dunn Gastritis (inflammation of the stomach); Etiologic agent - Helicobacter pylori (1). Transmission H. pylori infection
More informationHelicobacterPyloriandStepsforitsEliminationAReview
: F Diseases Volume 16 Issue 4 Version 1.0 Year 2016 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN: 0975-5888
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationThe significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus
University of Groningen The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus IMPORTANT NOTE: You are advised to consult the publisher's
More informationEradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin
CASE REPORT Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin Takahisa Furuta 1, Mitsushige Sugimoto 2, Mihoko Yamade
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:10.22034/APJCP.2017.18.4.927 Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole RESEARCH ARTICLE Outcomes of a Randomized Controlled Trial Comparing Modified High Dose
More informationProton pump inhibitor (proton pump inhibitor)-based triple therapies using clarithromycin in combination SUMMARY INTRODUCTION
Aliment Pharmacol Ther 2003; 18: 799 804. doi: 10.1046/j.1365-2036.2003.01764.x Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter
More informationPerspectives from Viet Nam
International Symposium I (Management of antibiotics-resistant Helicobacter pylori infection) Perspectives from Viet Nam Vu Van Khien 1,HoDangQuyDung 2, Tran Thanh Binh 2 1 Department of GI Endoscopy,
More informationHybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial
ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 1-6 Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial
More informationHelicobacter pylori resistance in the Netherlands: a growing problem?
ORIGINAL ARTICLE Helicobacter pylori resistance in the Netherlands: a growing problem? R. Ruiter 1,2 *, H.F. Wunderink 3, R.A. Veenendaal 5, L.G. Visser 4, M.G.J. de Boer 4 Departments of 1 Internal Medicine,
More informationManagement of H. pylori Resistance
Management of H. pylori Resistance Manfred Kist, Erik Glocker, Nicole Wüppenhorst, Beate Hobmaier National Reference Centre for Helicobacter pylori Institute of Medical Microbiology and Hygiene Freiburg,
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationHelicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師
Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for
More informationEfficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial
Journal of Antimicrobial Chemotherapy (2009) 63, 1017 1024 doi:10.1093/jac/dkp034 Advance Access publication 26 February 2009 Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationReview article: the global emergence of Helicobacter pylori antibiotic resistance
Alimentary Pharmacology and Therapeutics Review article: the global emergence of Helicobacter pylori antibiotic resistance I. Thung*,1, H. Aramin*,1, V. Vavinskaya*, S. Gupta,J.Y.Park, S. E. Crowe & M.
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationReceived 17 August 2010/Returned for modification 7 December 2010/Accepted 16 December 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAY, Mar. 2011, p. 1123 1129 Vol. 55, No. 3 0066-4804/11/$12.00 doi:10.1128/aac.01131-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Genotypic
More informationI. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD
A Randomized Double Blind Placebo Controlled Phase III Study to Assess the Safety and Efficacy of Rifabutin Triple Therapy (RHB-105) for Helicobacter pylori (H. pylori) Infection in Dyspepsia Patients
More information헬리코박터제균요법에있어서 CYP2C19 유전형이판토프라졸과라베프라졸포함치료법에미치는영향. Introduction 울산대학교의과대학서울아산병원소화기내과
The Korean Journal of Helicobacter and Upper Gastrointestinal Research Vol. 8, No. 1, 15-19, July 2008 Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: Comparison between Pantoprazole
More informationRates of clarithromycin resistance in Helicobacter pylori sampled from healthy subjects in Cheonan, Korea
Rates of clarithromycin resistance in Helicobacter pylori sampled from healthy subjects in Cheonan, Korea Young Sam Yuk 1, Ga-Yeon Kim 2 1. Department of Biomedical Laboratory Science, Dankook University
More informationRapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands.
Chapter 2 Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands. E.J.van der Wouden 1, A.A.van Zwet 2, J.C.Thijs 1, G.D.C.Vosmaer 3, J.A.J.Oom 4, A.de Jong
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationSusceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador
DOI: https://doi.org/.5/57.7 Susceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador Jorge Reyes Ch., Katherine Guzmán, Eduardo Morales,
More informationEfficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2012.15.4.237 Pediatric Gastroenterology, Hepatology & Nutrition 2012 December 15(4):237-242 Original Article PGHN Efficacy of Proton Pump
More informationClinical Study Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
BioMed Research International Volume 2015, Article ID 163960, 6 pages http://dx.doi.org/10.1155/2015/163960 Clinical Study Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationOriginal article J Bas Res Med Sci 2015; 2(4):45-50.
Comparison between the effectiveness of Furazolidone and Clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer Asghar Rahmani 1, Ali Jafari Haidarloo 2, Hoda Mabrokzadeh
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationHelicobacter pylori Eradication in Patients with an Iatrogenic Ulcer after Endoscopic Resection and Peptic Ulcer
ORIGINAL ARTICLE ISSN 1738-3331, https://doi.org/10.7704/kjhugr.2018.18.1.30 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018;18(1):30-37 Helicobacter pylori Eradication in
More informationTreatment for H. pylori Infection. New Challenges With Antimicrobial Resistance
CLINICAL REVIEW Treatment for H. pylori Infection New Challenges With Antimicrobial Resistance Nimish Vakil, MD, FACP, FACG, AGAF, FASGE* and Dino Vaira, MDw Abstract: The treatment of Helicobacter pylori
More informationClinical Study Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori Eradication: A Double-Blind, Randomized, and Controlled Trial
Gastroenterology Research and Practice Volume 2015, Article ID 818043, 5 pages http://dx.doi.org/10.1155/2015/818043 Clinical Study Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationHelicobacter and gastritis
1 Helicobacter and gastritis Dr. Hala Al Daghistani Helicobacter pylori is a spiral-shaped gram-negative rod. H. pylori is associated with antral gastritis, duodenal (peptic) ulcer disease, gastric ulcers,
More informationRifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study
Original Article Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study United European Gastroenterology Journal 2016,
More information헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구
Korean J Gastroenterol Vol. 70 No. 4, 176-180 https://doi.org/10.4166/kjg.2017.70.4.176 pissn 1598-9992 eissn 2233-6869 ORIGINAL ARTICLE 헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구 박혜윤, 강은정, 김동근, 김기주,
More informationAnalysis of Gene Mutations Associated with Antibiotic Resistance in Helicobacter pylori Strains Isolated from Korean Patients
ORIGINAL ARTICLE ISSN 1738-3331, http://dx.doi.org/10.7704/kjhugr.2014.14.2.95 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2014;14(2):95-102 Analysis of Gene Mutations Associated
More informationÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ
ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ 205 206 ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ EPITHELIAL CELL TURNOVER IN NON-DYSPLASTIC GASTRIC MUCOSA ADJACENT TO EARLY AND
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationRole of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication
Aliment Pharmacol Ther 2000; 14: 1639±1643. Role of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication S. TORACCHIO*, L. CELLINI, E.DICAMPLI, G.CAPPELLO*,M.G.MALATESTA*,A.FERRI*,
More informationHelicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:1032 1036 PERSPECTIVE Helicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results DAVID Y. GRAHAM Department of Medicine,
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationClinical Study Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade A Success Rate for First-Line Helicobacter pylori Eradication
BioMed Research International Volume 2015, Article ID 623732, 7 pages http://dx.doi.org/10.1155/2015/623732 Clinical Study Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade A Success
More informationRifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
Gut and Liver, Vol. 6, No. 4, October 2012, pp. 452-456 ORiginal Article Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori Sang-Pil Yun, Han Gyung Seon, Chang
More informationAntibiotic resistance in Helicobacter pylori infection
Antibiotic resistance in Helicobacter pylori infection Francis Megraud haboratoire de Bacteriologie, Hopital Pellegrin, Bordeaux, France Resistance to antibiotics is considered as the primary reason for
More informationCase 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie
Case 4: Peptic Ulcer Disease Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie Case 4: PUD Problem List: 1. Peptic Ulcer Disease SOAP Note: S Patient is complaining of abdominal pain
More informationDownloaded from:
Allison, R; ecky, DM; Bull, M; Turner, K; Godbole, G; Mculty, CA (2016) Audit of Helicobacter pylori Testing in Microbiology aboratories in England: To Inform Compliance with ICE Guidance and the Feasibility
More informationHelicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients
Gut and Liver, Vol. 9, No. 3, May 2015, pp. 346-352 ORiginal Article Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding
More informationHelicobacter pylori infection: antibiotic resistance and eradication rate in patients with gastritis showing previous treatment failures.
Short communication Helicobacter pylori infection: antibiotic resistance and eradication rate in patients with gastritis showing previous treatment failures. Maria Teresa Mascellino 1, Alessandra Oliva
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/59359
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationManagement of Helicobacter pylori infectiondthe Maastricht IV/ Florence Consensus Report
1 Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University of Magdeburg, Magdeburg, Germany 2 Department of Bacteriologie, INSERM U853, Université Bordeaux Segalen
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationThe Nobel Prize in Physiology or Medicine for 2005
The Nobel Prize in Physiology or Medicine for 2005 jointly to Barry J. Marshall and J. Robin Warren for their discovery of "the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer
More informationGilles Jequier. Commercial Director Organobalance, a Novozymes Company
"Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,
More informationTriple therapy versus sequential therapy for the first-line Helicobacter pylori eradication
Chang et al. BMC Gastroenterology (2017) 17:16 DOI 10.1186/s12876-017-0579-8 RESEARCH ARTICLE Open Access Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication Ji
More informationA Pilot Study of Helicobacter pylori Eradication Using a Polymerase Chain Reaction-based Test for Clarithromycin Resistance
ORIGINAL ARTICLE ISSN 1738-3331, https://doi.org/10.7704/kjhugr.2017.17.4.200 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017;17(4):200-207 A Pilot Study of Helicobacter pylori
More information02 MAR 16 Page 1 of 29. Prevention of Helicobacter pylori infection
02 MAR 16 Page 1 of 29 Sponsor: Investigational Product: Indication: Protocol Number: Protocol Title: Phase of Development: and Diagnostics GmbH & Co. KG Helicobacter pylori vaccine (HP) Prevention of
More informationRapidity of diagnosis and management of H. Pylori in the endoscopy unit at Mater Dei Hospital
Rapidity of diagnosis and management of H. Pylori in the endoscopy unit at Mater Dei Hospital Abstract Introduction: H.pylori infection has been associated with various gastric pathologies and its prevalence
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationHealth technology The use of four different combined treatments for Helicobacter pylori (H. pylori) infection. These were:
Tratamiento de la infeccion por Helicobacter pylori en pacientes con ulcera duodenal: estudio de costo-beneficio [Treatment of Helicobacter pylori infection in patients with duodenal ulcer: a cost-benefit
More informationLow-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
Blackwell Science, LtdOxford, UKJGHJournal of Gastroenterology and Hepatology0815-93192005 Blackwell Publishing Asia Pty Ltd206935940Original ArticleLow-dose rabeprazole-based triple therapywm Wong et
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More information1. Introduction. Chiba City , Japan 2 Department of Clinical Laboratory, Chiba University Hospital, Japan
International Scholarly Research Notices, Article ID 631501, 6 pages http://dx.doi.org/10.1155/2014/631501 Clinical Study Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication
More informationUpper Gastrointestinal Tract. Dr. Pascal Juillerat, M.Sc. epidemiology Gastroenterology, clinic for visceral surgery and medicine Inselspital, Bern
Upper Gastrointestinal Tract Dr. Pascal Juillerat, M.Sc. epidemiology Gastroenterology, clinic for visceral surgery and medicine Inselspital, Bern ? https://live.ueg.eu/week/app/ MONDAY Text GENETICS OR
More informationThe role of antisecretory drugs in the treatment of Helicobacter pylori infection
Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 21 25. The role of antisecretory drugs in the treatment of Helicobacter pylori infection W. L. PETERSON Department of Internal Medicine, University of Texas
More informationComparative study of invasive methods for diagnosis of Helicobacter pylori in humans
ISSN: 2319-7706 Volume 2 Number 7 (2013) pp. 63-68 http://www.ijcmas.com Original Research Article Comparative study of invasive methods for diagnosis of Helicobacter pylori in humans V.Subbukesavaraja
More informationHelicobacter pylori eradication an update on the latest therapies
Helicobacter pylori eradication an update on the latest therapies Author Yaxley, Julian, Chakravarty, Bhaskar Published 2014 Journal Title Australian Family Physician Copyright Statement 2014 Australian
More informationThe diagnosis and management of H. pylori infection in Singapore
Singapore Med J 2017; 58(5): 234-240 doi: 10.11622/smedj.2017037 CMEArticle The diagnosis and management of H. pylori infection in Singapore Claire Alexandra Zhen Chew 1, MBChB, Tong Fong Lye 2, MBBS,
More informationEfficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection
Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection Ramin Talaie Modarress Hospital, Shahid Beheshti University of Medical Sciences,
More informationPrevpac Pylera Omeclamox-Pak
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,
More informationPhenotypic and genotypic correlation as expressed in Helicobacter pylori resistance to clarithromycin and fluoroquinolones
DOI 10.1186/s13099-017-0198-5 Gut Pathogens RESEARCH Open Access Phenotypic and genotypic correlation as expressed in Helicobacter pylori resistance to clarithromycin and fluoroquinolones Dana Binyamin
More informationWork interest: Reviewer in the journals: Editorial board:
Name: Amin Last name: Talebi Bezmin Abadi Email: Amin.talebi@modares.ac.ir; Amin.talebi@gmail.com Birthday: 4 th December 1983 Birth Place: Sari, Mazandaran Province, Iran B.S: Biology, University of Golestan,
More informationUse of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori
Alimentary Pharmacology and Therapeutics Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori J. C. Delchier*,
More informationORIGINAL INVESTIGATION. Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting
ORIGINAL INVESTIGATION Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting M. Brian Fennerty, MD; David A. Lieberman, MD; Nimish Vakil, MD; Nathan Magaret; Douglas O. Faigel,
More informationSystematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure
Alimentary Pharmacology & Therapeutics Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure J. P. GISBERT & F. DE LA MORENA Department of
More informationArab Journal of Gastroenterology
Arab Journal of Gastroenterology 14 (2013) 1 5 Contents lists available at SciVerse ScienceDirect Arab Journal of Gastroenterology journal homepage: www.elsevier.com/locate/ajg Original Article Penbactam
More information